Monopar Therapeutics
Monopar Therapeutics Inc. (Nasdaq Capital Market: MNPR) is a clinical-stage biopharmaceutical company developing innovative treatments for Wilson disease and novel radiopharmaceuticals for oncology. The company's website is www.monopartx.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Monopar Therapeutics does
In the company’s own words
Monopar Therapeutics Inc. (Nasdaq Capital Market: MNPR) is a clinical-stage biopharmaceutical company developing innovative treatments for Wilson disease and novel radiopharmaceuticals for oncology. The company's website is www.monopartx.com.
The company's primary product candidate is ALXN1840, a late-stage investigational once-daily oral medicine for Wilson disease, a rare genetic condition characterized by toxic copper accumulation in the liver and brain. ALXN1840 has received Orphan Drug Designation in the U.S. and European Union, as well as Fast Track designation from the FDA. A completed pivotal Phase 3 clinical trial demonstrated that ALXN1840 achieved three-times greater copper mobilization compared to standard-of-care treatment, with sustained improvements in neurological and psychiatric symptoms observed over multiple years of treatment. The company acquired exclusive worldwide rights to ALXN1840 from Alexion Pharmaceuticals in October 2024 and currently plans to submit a New Drug Application to the FDA in mid-2026.
Monopar's radiopharmaceutical programs target urokinase plasminogen activator receptor, or uPAR, which is highly expressed on aggressive cancers including pancreatic, breast, ovarian, and bladder tumors. The company is developing MNPR-101-Zr as a Phase 1 imaging and dosimetry agent, MNPR-101-Lu as a Phase 1a therapeutic candidate using lutetium-177, and MNPR-101-Ac as a late-preclinical therapeutic using actinium-225. Clinical trials for the imaging and therapeutic candidates are actively enrolling patients in Australia, and the company received FDA clearance for an Expanded Access Program in the United States in June 2025.
The company builds its drug development pipeline through both internal research efforts and licensing of late-stage therapeutics. Monopar has established collaborations with NorthStar Medical Radioisotopes for radioisotope supply and intellectual property development, and holds a non-exclusive license to XOMA's antibody humanization technology. The company depends on third-party contract manufacturers for all pharmaceutical and biologic manufacturing requirements.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- WILMETTE, IL
- Fiscal year end
- December
- CIK
- 1645469
- SIC
- 2834
Financial performance, year by year
Fiscal 2017–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Monopar Therapeutics — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Monopar Therapeutics’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Monopar Therapeutics and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Monopar Therapeutics's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Monopar Therapeutics's last four quarterly filings that the numbers alone won't show?”